Incidence and Risk of Hypertension with Ramucirumab in Cancer Patients: A Meta-Analysis of Published Studies

Clinical Drug Investigation

Volumn 35, Issue 4, 2015, Pages 221-228

  Wang, Jianhua ^a   Wang, Zexing ^b   Zhao, Yunzhao ^c  

^a Laboratory of Cellular and Molecular Biology Jiangsu Province Institute of Traditional Chinese Medicine   (China)

^b WANNAN MEDICAL COLLEGE   (China)

^c MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

RAMUCIRUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY;

ADENOCARCINOMA; ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CARDIOVASCULAR RISK; DRUG INDUCED DISEASE; ESOPHAGEAL ADENOCARCINOMA; GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LOWER ESOPHAGUS SPHINCTER; MELANOMA; META ANALYSIS; MONOTHERAPY; MULTIPLE CANCER; NON SMALL CELL LUNG CANCER; OVARY CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STOMACH ADENOCARCINOMA; SYSTEMATIC REVIEW; ADULT; AGED; CHEMICALLY INDUCED; COMPLICATION; FEMALE; INCIDENCE; MALE; MIDDLE AGED; NEOPLASMS; RISK FACTOR; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; HYPERTENSION; INCIDENCE; MALE; MIDDLE AGED; NEOPLASMS; RISK FACTORS; YOUNG ADULT;

EID: 84925485366     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/s40261-015-0272-z     Document Type: Article

References (36)

1. Liguigli W, Tomasello G, Toppo L, et al. Ramucirumab for metastatic gastric or gastroesophageal junction cancer: results and implications of the REGARD trial. Future Oncol. 2014;10:1549–57.
2. Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383:31–9.
3. ClinicalTrials.gov: List results, search of ramucirumab. http://clinicaltrials.gov/ct2/results?term=Ramucirumab. Accessed 20 Sept 2014.
4. Garon EB, Ciuleanu TE, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014;384:665–73.
5. Poole RM. Vaidya a ramucirumab: first global approval. Drugs. 2014;74:1047–58.
6. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.
7. Bendell JC, Braiteh FS, Firdaus I, et al. Ramucirumab (RAM) plus FOLFOX as front-line therapy (Rx) for advanced gastric or esophageal adenocarcinoma (GE–AC): randomized, double-blind, multicenter phase 2 trial. J Clin Oncol. 2014;32:5s (suppl; abstr 4004).
8. Zhu AX, Finn RS, Mulcahy M, et al. A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer. Clin Cancer Res. 2013;19:6614–23.
9. Camidge DR, Berge EM, Doebele RC, et al. A phase II, open-label study of ramucirumab in combination with paclitaxel and carboplatin as first-line therapy in patients with stage iiib/iv non-small-cell lung cancer. J Thorac Oncol. 2014;9:1532–9.
10. Carvajal RD, Wong MK, Thompson JA, et al. A phase 2 randomised study of ramucirumab (IMC-1121B) with or without dacarbazine in patients with metastatic melanoma. Eur J Cancer. 2014;50:2099–107.
11. Garcia JA, Hudes GR, Choueiri TK, et al. A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy. Cancer. 2014;120:1647–55.
12. Garcia-Carbonero R, Rivera F, Maurel J, et al. An open-label phase II study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy for metastatic colorectal cancer. Oncologist. 2014;19:350–1.
13. Mackey JR, Ramos-Vazquez M, Lipatov O, et al. Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase iii trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer. J Clin Oncol. 2014. doi:10.1200/JCO.2014.57.1513.
14. Penson RT, Moore KM, Fleming GF, et al. A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma. Gynecol Oncol. 2014;134:478–85.
15. Wilke H, Muro K, Van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15:1224–35.
16. Yardley DA, Richards PD, Reeves JA, et al. Final results of a phase 2 study of ramucirumab (RAM) plus eribulin (E) versus E in advanced metastatic breast cancer (MBC). J Clin Oncol. 2014;32:5s (suppl; abstr 1035).
17. Ranpura V, Pulipati B, Chu D, et al. Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens. 2010;23:460–8.
18. Zhu X, Stergiopoulos K, Wu S. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol. 2009;48:9–17.
19. An MM, Zou Z, Shen H, et al. Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated meta-analysis. Eur J Clin Pharmacol. 2010;66:813–21.
20. Wu S, Chen JJ, Kudelka A, et al. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol. 2008;9:117–23.
21. Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst. 2007;99:1232–9.
22. Qi WX, Shen Z, Lin F, et al. Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials. Br J Clin Pharmacol. 2013;76:348–57.
23. Qi WX, Lin F, Sun YJ, et al. Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis. Cancer Chemother Pharmacol. 2013;71:431–9.
24. Rixe O, Billemont B, Izzedine H. Hypertension as a predictive factor of Sunitinib activity. Ann Oncol. 2007;18(6):1117.
25. Rini BI, Cohen DP, Lu DR, et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst. 2011;103:763–73.
26. Estfan B, Byrne M, Kim R. Sorafenib in advanced hepatocellular carcinoma: hypertension as a potential surrogate marker for efficacy. Am J Clin Oncol. 2012;36:319–24.
27. Gampenrieder SP, Romeder F, Muss C, et al. Hypertension as a predictive marker for bevacizumab in metastatic breast cancer: results from a retrospective matched-pair analysis. Anticancer Res. 2014;34:227–33.
28. Lankhorst S, Kappers MH, van Esch JH, et al. Hypertension during vascular endothelial growth factor inhibition: focus on nitric oxide, endothelin-1, and oxidative stress. Antioxid Redox Signal. 2014;20:135–45.
29. Bouallegue A, Daou GB, Srivastava AK. Endothelin-1-induced signaling pathways in vascular smooth muscle cells. Curr Vasc Pharmacol. 2007;5:45–52.
30. Kappers MH, de Beer VJ, Zhou Z, et al. Sunitinib-induced systemic vasoconstriction in swine is endothelin mediated and does not involve nitric oxide or oxidative stress. Hypertension. 2012;59:151–7.
31. Kappers MH, Smedts FM, Horn T, et al. The vascular endothelial growth factor receptor inhibitor sunitinib causes a preeclampsia-like syndrome with activation of the endothelin system. Hypertension. 2011;58:295–302.
32. Banfor PN, Franklin PA, Segreti JA, et al. ETA receptor blockade with atrasentan prevents hypertension with the multitargeted tyrosine kinase inhibitor ABT-869 in telemetry-instrumented rats. J Cardiovasc Pharmacol. 2009;53:173–8.
33. Langenberg M, Van Herpen C, De Bono J, et al. Optimal management of emergent hypertension during treatment with a VEGF signaling inhibitor: a randomized phase II study of cediranib. J Clin Oncol. 2008;26(suppl):abstr 3555.
34. Izzedine H, Ederhy S, Goldwasser F, et al. Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol. 2009;20:807–15.
35. Pinto A, Merino M, Zamora P, et al. Targeting the endothelin axis in prostate carcinoma. Tumour Biol. 2012;33:421–6.
36. Groenewegen G, Walraven M, Vermaat J, et al. Targeting the endothelin axis with atrasentan, in combination with IFN-alpha, in metastatic renal cell carcinoma. Br J Cancer. 2012;106:284–9.